Northern Light Pharmacy (M Drug, LLC), Bangor, ME
Is Northern Light Pharmacy (M Drug, LLC) registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Northern Light Pharmacy (M Drug, LLC) hold a Maine pharmacy license?
State board of pharmacy records for Maine are not checked: this index has not yet added that board’s records. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0003611 for M DRUG LLC (dba NORTHERN LIGHT PHARMACY), BANGOR, ME, status ACTIVE (CURRENT), as of Nov 15, 2026.
Has Northern Light Pharmacy (M Drug, LLC) had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 state referral letter (Apr 1, 2020) and 1 FMD-145 letter (Apr 1, 2020) for Northern Light Pharmacy (M Drug, LLC). State board of pharmacy records for Maine are not checked: this index has not yet added that board’s records. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- M Drug, LLC; Northern Light Pharmacy
- Location
- Bangor, ME
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Apr 1, 2020
- FDA Data Dashboard inspections
- 1 inspection: 1 VAI; 0 published Form 483s
- Form 483 text on this page
- 1 Form 483, 3 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as M Drug, LLC, (dba Northern Light Pharmacy), a 503A facility, with 3 dated actions.
| Document | |||
|---|---|---|---|
| Apr 1, 2020 | State referral letter | State Referral Letter Issued 04/01/2020 | FDA copy (archived) |
| Apr 1, 2020 | FMD-145 letter | FMD-145 Letter Issued 04/01/2020 | FDA copy (archived) |
| Aug 20, 2019 | Amended Form 483 | Amended 483 Issued 08/20/2019 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists M Drug, LLC, Bangor, ME (FEI number 3002159099), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Jul 19, 2019 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3002159099 | 1096790 |
Form 483s FDA has published for this site
No published Form 483 for FEI 3002159099 was found in the dashboard’s list of published 483s on Nov 15, 2026. FDA publishes only some 483s, so this does not mean none was issued.
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 3 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Jul 16, 2019 to Jul 19, 2019: 3 observations
- Firm on the cover
- M Drug, LLC dba Northern Light Pharmacy, 210 State St, Bangor, ME 04401-5411
- FEI number
- 3002159099
- Establishment type on the cover
- Producer of Drug Products
- FDA district office on the cover
- One Montvale Avenue St oneham, MA 02180
- Matched to this page by
- FEI number on the cover; linked from actions page
- FDA document
- Read the full 483 (Internet Archive copy FDA links)
Observation 1
You produced hazardous drugs without providing adequate containment, segregation, cleaning of work surfaces and cleaning of utensils to prevent cross-contamination.
Specifically:
You produce hazardous drugs in your non-dedicated compounding facility including Tacrolimus (cytotoxic) without providing adequate containment, segregation, cleaning of work surfaces, and cleaning of non-dedicated drug product contact utensils to prevent cross contamination with other hazardous and non-hazardous drug products.
The following deficiencies were observed in your compounding facility and production practices:
A. There is no designed control of airflow or other engineered containment of hazardous compounds processed in the open on the compounding bench. Process steps <Redacted B4>
[1:5) (4)
B. Clean non-dedicated compounding equipment including <Redacted B4>, and <Redacted B4> are stored exposed in racks and shelving adjacent to the compounding bench.
AMENDMENT 1
D. Compounding room work surfaces are not cleaned by methods and cleaning agents shown to remove or de-activate hazardous df <Redacted B4> compound residues.
E. ...
Observation 2
Your facility design allowed the influx of poor quality air into a higher classified area.
Specifically:
Your compounding facility is not designed and operated to provide adequate control of microorganisms and environmental paiiiculates to prevent objectionable contamination of non-sterile compounded drug products. The following deficiencies in your compounding facility, practices, and equipment were observed:
There is no designed control of airflow direction, pressure differential, and personnel and equipment movement between the compounding room and adjacent uncontrolled areas to exclude airborne and transported foreign particulates and microorganisms that may contaminate drug products. Furthermore,:
a. A window mounted air conditioner is operated in the compounding room above and adjacent to the compounding bench. The air conditioner was observed to have visible paiiiculate residues in the vents. There were gaps with light visible between the air conditioner and window frame. There is no pre-filtration of intake air to the air conditioner unit.
AMENDMENT 1
to the compounding bench. The air conditioner was observed to have visible paiiiculate residues in the vents. ...
Observation 3
Your Firm released drug product in which the strength differs from, or its purity or quality falls below, that which it purports or is represented to possess.
Specifically:
A. You do not have data to show that your electronic balance, used to weigh drug components including active phaimaceutical ingredients (API) for formulation of compounded drug products, can deliver accurate and repeatable results ensuring that the correct amounts of drug components are added to the drug product. Your electronic balance « <Redacted B4> used to weigh drug components including APis for formulation of drug products was not calibrated. Your last service record for the balance from 2009 indicates that a calibration check passed. Furthermore:
AMENDMENT 1
a. You do not have specifications for the minimum and maximum capacity of the balance and you have not established the acceptable user range.
b. You do not routinely perfo1m and document balance calibration checks.
B. I observed that the compounding Phaimacy Technician did not use a measuring device to ensure accurate addition of the excipient <Redacted B4> of several <Redacted B4> drug products. ...
State board of pharmacy records
State board of pharmacy records for Maine are not checked: this index has not yet added that board’s records.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| PCN.0003611 | NONRESIDENT PHARMACY | M DRUG LLC (dba NORTHERN LIGHT PHARMACY) | BANGOR, ME | ACTIVE (CURRENT) |
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Connecticut Department of Consumer Protection license file
Records last pulled Nov 15, 2026. Every entry links to the original public record.